All News
ESMO 2023 | Ascentage Pharma to Present Results from Two Clinical Studies, including One Oral Presentation, at 2023 ESMO Congress
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it is going to release results from two clinical studies at the 2023 European Society of Medical Oncology (ESMO) Congress.
MANA Develops Novel “Drycell” Microdroplets to Make Handling Single Cell Easier
Scientists at the Research Center for Materials Nanoarchitectonics (MANA) have developed micrometer-sized "liquid marbles" that can encapsulate single to several living cells, thereby aiding single-cell studies.
JinMed’s Nanobathing Products Receive Multiple Patent Certifications and Sign Directed Procurement Agreement with Shanghai Zhongjin HongKang Medical Technology
JinMed has signed a directed procurement agreement for bed-type nanothermal therapy bath cabins with Shanghai Zhongjin HongKang Medical Technology Co., Ltd.
SK Biopharmaceuticals Assembles ‘Board of Prominent Experts’ to Boost Growth, Innovation
SK Biopharmaceuticals, a global biotech company, announced the formation of its Scientific Advisory Board (SAB), comprising of five prominent experts in oncology, epilepsy, and radiopharmaceutical therapy.
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in its Phase 1 clinical trial of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR mutations.
Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer
Molecular Targeting Technologies, Inc. (MTTI), and its wholly owned subsidiary, Molecular Theranostic Center of Singapore (MTCS), announced the approval of a Clinical Trial Authorization (CTA) application by the Health Sciences Authority (HSA) of Singapore.
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the second quarter of 2023 and business highlights.
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics’ Licensed Allogeneic CAR-Gamma Delta T Cell Technology
CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, which is exclusively licensed from the Agency for Science, Technology and Research (A*STAR), has been granted a patent by the China National Intellectual Property Administration (CNIPA).
Innoforce Strengthens Commercialization Leadership and Announces the Appointment of a New Chief Executive Officer
Zhejiang Innoforce Pharmaceuticals Co., Ltd. ("Innoforce"), a CDMO company dedicated to providing one-stop-shop services to Advanced Therapy Medicinal Product (ATMP) customers and partners, today announced Dr. Dewan Zeng as the new Chief Executive Officer, effective immediately.
Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval From NMPA
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Glucagon-like peptide-1 receptor (GLP-1R), Glucagon receptor (GCGR), and Fibroblast growth factor 21 receptor (FGF21R), has completed the dosing of the first subject in the Phase Ib 12-week Multiple-Ascending Dose (MAD) study of DR10624 for the treatment of obesity and hypertriglyceridemia in New Zealand.
